Toumpeki Chrisavgi, Liberis Anastasios, Tsirkas Ioannis, Tsirka Theodora, Kalagasidou Sofia, Inagamova Lola, Anthoulaki Xanthoula, Tsatsaris Georgios, Kontomanolis Emmanuel N
Department of Obstetrics and Gynecology, Democritus University of Thrace, Alexandroupolis, Greece.
Second Department of Obstetrics and Gynecology, Hippokration General Hospital, Thessaloniki, Greece.
In Vivo. 2019 May-Jun;33(3):659-667. doi: 10.21873/invivo.11524.
AT-rich interaction domain 1A gene (ARID1A) encodes for a subunit of the switch/sucrose non-fermentable (SWI/SNF) complex, a chromatin remodeling complex, and it has been implicated in the pathogenesis of various cancer types. In this review, we discuss how ARID1A is linked to endometrial cancer and what molecular pathways are affected by mutation or inhibition of ARID1A. We also discuss the potential use of ARID1A not only as a prognostic biomarker, but also as a target for therapeutic interventions.
富含AT的相互作用结构域1A基因（ARID1A）编码一种开关/蔗糖非发酵（SWI/SNF）复合物的亚基，该复合物是一种染色质重塑复合物，并且它与多种癌症类型的发病机制有关。在本综述中，我们讨论了ARID1A如何与子宫内膜癌相关联，以及ARID1A的突变或抑制会影响哪些分子途径。我们还讨论了ARID1A不仅作为一种预后生物标志物的潜在用途，而且作为治疗干预靶点的潜在用途。
